Pfizer Inc. (PFE)
| Market Cap | 160.82B |
| Revenue (ttm) | 55.09B |
| Net Income (ttm) | -309.00M |
| Shares Out | 5.67B |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 10.79 |
| Dividend | $1.68 (5.92%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 22,325,371 |
| Open | 28.55 |
| Previous Close | 28.44 |
| Day's Range | 28.19 - 28.68 |
| 52-Week Range | 25.20 - 40.37 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 36.00 (+26.85%) |
| Earnings Date | May 1, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $36.0, which is an increase of 26.85% from the latest price.
News
Final Trades: Pfizer, Vertex, Freeport-McMoran and Qualcomm
The Investment Committee give you their top stocks to watch for the second half.
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO , May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and ...
Pfizer's next move: Can it break above $30?
Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. However, recent developments suggest a potential turnaround for the pharm...
3 Dividend Stocks for May 2024
The dividend prospects of three firms with wide or narrow Morningstar Economic Moat Ratings.
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France
Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business ...
A Struggling Pfizer Looks for Help From a Wall Streeter
As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn't recommended the stock in over a decade. But Andrew Baum has something Pfizer ...
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
The lawsuits were filed in state courts nationwide, but the agreements don't completely resolve Pfizer's exposure to claims linking Zantac and cancer.
Pfizer agrees to settle more than 10,000 Zantac cancer lawsuits - Bloomberg News
Pfizer Inc has agreed to settle more than 10,000 cases about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the d...
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told ...
Pfizer Dividend Yield Pushes Past 6%
In trading on Tuesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.91 on the day. Dividends are ...
Is Pfizer Stock Fully Valued At $28?
Pfizer Pfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates. The company reported revenue of $14.9 billion and an adjusted profit of $0.82 per ...
Pfizer Announces New Chief Strategy and Innovation Officer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a ...
Josh Brown buys more Pfizer
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's Halftime Report' to explain why he's doubling down on Pfizer.
Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce A $50 Million Class Action Settlement with Pfizer on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen
NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: COURT-ORDERED LEGAL NOTICE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS If you purchased EpiPen® or generi...
Pfizer Stock Gets Boost From Better-Than-Expected Earnings
Pfizer (PFE) shares rose Wednesday after first-quarter earnings and revenue fell less than expected, with the decline partially offset by sales growth in the company's non-COVID-related products.
Pfizer beats revenue estimates - raises profit outlook on cost cuts and strong non-Covid sales
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business.
Pfizer first-quarter results top estimates, drugmaker boosts full-year profit outlook
Pfizer Inc. shares PFE, -0.08% gained 1.5% premarket on Wednesday after the company reported first-quarter profit and sales that beat analyst expectations, boosted by strong sales of its Vyndaqel fami...
Pfizer's 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low
Pfizer comfortably beat expectations in its quarterly earnings report Wednesday morning, as the American pharmaceutical giant attempts to regain its footing as the COVID-19 pandemic subsides.
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
Pfizer Inc. (NYSE: PFE) has announced its financial outcomes for the first quarter of 2024, displaying strong performance in its non-COVID product portfolio. This includes heightened revenues from rec...
Pfizer beats profit estimates on cost cuts, RSV vaccine sales
Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and respiratory synctitial virus vaccines.
Pfizer Reports First-Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of it...
Pfizer, Genmab get full FDA approval for cervical-cancer drug
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...